CL2020001814A1 - Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble. - Google Patents

Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.

Info

Publication number
CL2020001814A1
CL2020001814A1 CL2020001814A CL2020001814A CL2020001814A1 CL 2020001814 A1 CL2020001814 A1 CL 2020001814A1 CL 2020001814 A CL2020001814 A CL 2020001814A CL 2020001814 A CL2020001814 A CL 2020001814A CL 2020001814 A1 CL2020001814 A1 CL 2020001814A1
Authority
CL
Chile
Prior art keywords
preparation
intermediates
guanylate cyclase
soluble guanylate
stimulants
Prior art date
Application number
CL2020001814A
Other languages
English (en)
Inventor
Song Xue
Vishnu Vardhan Reddy Karnati
Wayne C Schairer
Ahmad Hashash
Takashi Nakai
Debra Jane Wallace
Fenger Zhou
Yuguang Wang
William Kissel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed filed Critical
Publication of CL2020001814A1 publication Critical patent/CL2020001814A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procesos nuevos para la preparación de compuestos de Fórmula I. Algunos de estos compuestos son de utilidad como estimulantes de la guanilato ciclasa soluble (sGC). Otros son intermediarios para usar en la preparación de dichos estimulantes. Estos procesos son adecuados para preparaciones a gran escala y producen 3-(2-pirimidinil)pirazoles de la Fórmula I estables, de gran pureza y rendimientos elevados. La invención ofrece la ventaja adicional de comprender condiciones de reacción sencillas, adecuadas para aumentar la escala en una producción a gran escala. También se proveen nuevos intermediarios para usar en la preparación de dichos compuestos.
CL2020001814A 2018-01-10 2020-07-07 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble. CL2020001814A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
CL2020001814A1 true CL2020001814A1 (es) 2020-11-06

Family

ID=65279655

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020001814A CL2020001814A1 (es) 2018-01-10 2020-07-07 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
CL2022000904A CL2022000904A1 (es) 2018-01-10 2022-04-08 Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
CL2022000907A CL2022000907A1 (es) 2018-01-10 2022-04-08 Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2022000904A CL2022000904A1 (es) 2018-01-10 2022-04-08 Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
CL2022000907A CL2022000907A1 (es) 2018-01-10 2022-04-08 Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814).

Country Status (17)

Country Link
US (2) US11274096B2 (es)
EP (2) EP4249469A3 (es)
JP (2) JP7357621B2 (es)
KR (1) KR20200106920A (es)
CN (3) CN118221665A (es)
AU (2) AU2019206560B2 (es)
BR (1) BR112020013985A2 (es)
CA (1) CA3087943A1 (es)
CL (3) CL2020001814A1 (es)
ES (1) ES2963447T3 (es)
IL (1) IL275748A (es)
JO (1) JOP20200165A1 (es)
MA (1) MA51565A (es)
MX (3) MX2020007364A (es)
SG (1) SG11202006311SA (es)
TW (2) TW202402741A (es)
WO (1) WO2019140095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077A (zh) * 2016-07-07 2019-04-02 铁木医药有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
TW202402741A (zh) 2018-01-10 2024-01-16 美商賽克瑞恩醫療公司 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
CN109369635B (zh) * 2013-03-15 2023-06-30 赛克里翁治疗有限公司 化合物或其药学上可接受的盐及其应用和药物组合物
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CA2961531A1 (en) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR20180086497A (ko) * 2015-11-30 2018-07-31 아이언우드 파마슈티컬스, 인코포레이티드 sGC 자극제를 포함하는 고체 분산물
JP7054395B2 (ja) 2016-07-07 2022-04-13 サイクレリオン・セラピューティクス,インコーポレーテッド 可溶性グアニル酸シクラーゼ刺激剤の新規な調製方法
CN109563077A (zh) 2016-07-07 2019-04-02 铁木医药有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
TW202402741A (zh) 2018-01-10 2024-01-16 美商賽克瑞恩醫療公司 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物

Also Published As

Publication number Publication date
CN111902410A (zh) 2020-11-06
US20220024909A1 (en) 2022-01-27
CL2022000907A1 (es) 2022-10-21
TW201932450A (zh) 2019-08-16
CL2022000904A1 (es) 2022-10-21
CN111902410B (zh) 2024-04-19
JP2021511299A (ja) 2021-05-06
AU2019206560B2 (en) 2023-08-24
US20210053962A1 (en) 2021-02-25
WO2019140095A8 (en) 2020-06-18
EP4249469A3 (en) 2023-12-27
KR20200106920A (ko) 2020-09-15
TW202402741A (zh) 2024-01-16
BR112020013985A2 (pt) 2020-12-01
MX2023000044A (es) 2023-02-01
CA3087943A1 (en) 2019-07-18
MX2020007364A (es) 2020-11-18
JP7357621B2 (ja) 2023-10-06
CN118221665A (zh) 2024-06-21
ES2963447T3 (es) 2024-03-27
JP2023182647A (ja) 2023-12-26
US11274096B2 (en) 2022-03-15
EP4249469A2 (en) 2023-09-27
US11708361B2 (en) 2023-07-25
US20230339928A1 (en) 2023-10-26
EP3737679C0 (en) 2023-09-06
MX2023000045A (es) 2023-02-01
AU2019206560A1 (en) 2020-07-30
MA51565A (fr) 2020-11-18
EP3737679B1 (en) 2023-09-06
IL275748A (en) 2020-08-31
SG11202006311SA (en) 2020-07-29
AU2023270260A1 (en) 2023-12-07
CN118184645A (zh) 2024-06-14
JOP20200165A1 (ar) 2022-10-30
WO2019140095A1 (en) 2019-07-18
EP3737679A1 (en) 2020-11-18
TWI821237B (zh) 2023-11-11

Similar Documents

Publication Publication Date Title
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CL2022000904A1 (es) Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
PH12019502386A1 (en) Process for preparing s-containing pyrimidinium compounds
MX2022001495A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
MX2018014130A (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
MX2022008676A (es) Sintesis de (e)-1,1,1,4,5,5,5-heptafluoro-4-(trifluorometil)pent-2 -eno.
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
EA201991887A1 (ru) Замещенные эфиры бензил-4-аминопиколиновой кислоты и эфиры пиримидин-4-карбоновой кислоты, способы их получения, а также их применение в качестве гербицидов и регуляторов роста
EA202091664A1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
PL409652A1 (pl) Sposób epoksydacji limonenu
PL412140A1 (pl) Sposób otrzymywania 1,4-dwupodstawionych 1,2,3-Triazoli w reakcji cykloaddycji lub w syntezie one pot, z udziałem katalizatorów
MX2021011405A (es) Mezclas de tintes de alta dispersion rapida en humedo.
CY1120153T1 (el) Μεθοδος για την παρασκευη 19-νορπρεγκν-4-εν-3,20-διονο-17.αλφα.-ολης (gestonorone) και ενδιαμεσων αυτης
UA110455C2 (en) METHOD FOR SPIRO-λ6-IZOTIAZOLIDYN-1,1,4-TRION
EA202091499A1 (ru) Синтез алкил 2-ацетил-5,9,13-триметилтетрадека-4,8,12-триеноатов и их производных периодическим способом
UA123716U (uk) Обетіхолева кислота
CY1125227T1 (el) Μορφες δοσολογιας που περιλαμβανουν αναστολεα kαλλικρεϊνης πλασματος
AR125001A1 (es) Procesos para preparar moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EA201691661A1 (ru) Способ получения производных 21-метокси-11-бета- фенил-19-норпрегна-4,9-диен-3,20-диона
AR099185A1 (es) Método para producir un compuesto purificado de benzoxazina